west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "进展期胃癌" 31 results
  • Intraperitoneal Hyperthermic Perfusion Chemotherapy for Postoperative Advanced Gastric Cancer: A Systematic Review

    Objective To evaluate the effectiveness and safety of postoperative intraperitoneal hyperthermic perfusion chemotherapy (IHPC) for advanced gastric cancer, so as to provide references for clinical practice and study. Methods The following databases including The Cochrane Library, PubMed, EMbase, CBM, CNKI, VIP and WanFang were searched on computer, and other searches were also performed to collect all relevant randomized controlled trials (RCTs) on postoperative IHPC versus intravenous chemotherapy alone (IC) for advanced gastric cancer. The quality of the included studies was assessed according to Cochrane Handbook 5.1 for Systematic Review, and Meta-analysis was conducted by using RevMan 5.1 software. Results A total of 18 RCTs involving 2299 patients were included. The results of meta-analyses showed that: a) Efficacy evaluation: There were significant differences between the IHPC group and the IC group in 1-, 2-, 3-, and 5-year survival rate, 3- and 5-year recurrence rate, and 3- and 5-year distant metastasis rate; the OR value and 95%CI were 1.88 (1.49, 2.39), 2.45 (1.64, 3.67), 2.29 (1.92, 2.73), 2.17 (1.70, 2.76), 0.39 (0.29, 0.52), 0.54 (0.40, 0.72), 0.55 (0.38, 0.78), 0.58 (0.42, 0.81), respectively; b) Safety evaluation: There were significant differences between the IHPC group and the IC group in the incidence of abdominal pain, abdominal distension, nausea and vomiting; the OR value and 95%CI were 2.20 (1.58, 3.07), 7.00 (2.67, 18.36), 0.65 (0.45, 0.95), respectively. But there were no significant differences between the IHPC group and the IC group in the incidence of alopecia, ileus, bone marrow inhibition, and hepatic lesion. Conclusion Compared with IC, postoperative IHPC+IC can improve survival rate and reduce the recurrence and distant metastasis rate; additionally, it is safe and feasible, so it is recommended that the detailed condition of patients should be taken into consideration when the postoperative IHPC+IC therapy is applied to clinic.

    Release date: Export PDF Favorites Scan
  • Application of Cisplatin in Bletilla Hyacinthine Particle Chemotherapy Combined with 125Iodine Brachytherapy in Advanced Gastric Cancer

    Objective To observe the effect of cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy on short-and long-term outcomes and the toxic and side effects in advanced gastric cancer. Methods One hundred seventy-six patients with stage Ⅱ or stage Ⅲ advanced gastric cancer underwent curative surgical resection were included in this study. They were randomly divided into brachytherapy and chemotherapy group (n=48), intraperitoneal chemotherapy group (n=32) and intravenous chemotherapy group (n=48), and other patients who abandoned radiotherapy and chemotherapy and signed informed consent form by themselves were considered as control group (n=48). The short-and long-term outcomes and the toxic and side effects were observed and the survival of all patients was analyzed by Kaplan-Meier method and Log-Rank test. Results For short-term outcomes, the total effective rate in 4 groups were 95.83%, 71.88%, 64.58% and 52.08% respectively, and the difference was significant (Plt;0.05). For long-term outcomes, the 3 -and 5-year mortality rate was 37.50% and 56.30%, and 5-year median survival time was (14±4.51) months (95%CI: 14.419-4.512) in brachytherapy and chemotherapy group patients. The 3- and 5-year mortality rate was 78.12%and 93.75%and 5year median survival time was (10.6±1.13) months (95%CI: 10.620-1.163) in intraperitoneal chemotherapy group patients. The 3-and 5-year mortality rate was 79.21%and 95.80%and 5-year median survival time was (11±3.10) months (95%CI: 11.130-3.162) in intravenous chemotherapy group patients. The 3-and 5-year mortality rate was 87.50%and 95.83% and 5-year median survival time was (9±2.30) months (95%CI: 10.024-1.180) in control group patients. Compared with the vein chemotherapy group, the short distance puts the chemotherapy group disgusting vomit, the marrow to suppress, the liver function harm, the kidney function harm formation rate to reduce obviously (Plt;0.05). Conclusion Cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy can reduce the toxic and side effects of drugs and prolong survival time of patients with advanced gastric cancer.

    Release date:2016-09-08 10:50 Export PDF Favorites Scan
  • Current Status of Multimodal Therapy for A vanced Gastric Carcinoma

    Objective  To review the research advancement of multimodal therapy for advanced gast ric carcinoma. Methods  The literatures on multimodal therapy for advanced gastric carcinoma in recent years were collected and reviewed. Results  The multimodal therapy , such as preoperative chemotherapy , preoperative adjuvant chemoradiotherapy , preoperative interventional chemoradiotherapy for advanced gast ric carcinoma was effective because it could increase the rate of R0 resection for the patients with advanced gastric carcinoma. And it can decrease the mortality rate after operation , extend the overall survival time and improve patients’life quality. Conclusion  Multimodal therapy is a promising method for the treatment of advanced gastric carcinoma and it should be further developed.

    Release date: Export PDF Favorites Scan
  • Current Status on Clinical Therapy for Advanced Gastric Carcinoma

    【Abstract】ObjectiveTo discuss how to improve the current status on clinical therapy for advanced gastric carcinoma. MethodsRelated literatures searched on Medline were collected and reviewed. ResultsThe 5th edition of UICC/AJCC TNM staging system of gastric carcinoma is useful to evaluate the prognosis of patients with advanced gastric carcinoma followed by extended lymphadenectomy. There are many factors influencing their prognosis including disease stage, extent of lymphadenectomy, assistant therapy and so on. ConclusionIt is significant for patients with advanced gastric carcinoma to undergo individualized extended lymphadenectomy and comprehensive therapy to improve their prognosis after radical gastrectomy

    Release date:2016-08-28 04:20 Export PDF Favorites Scan
  • Efficacy and Safety of Intraoperative Mesenchymal Chemotherapy with 5-Fluorouracil Release Formulation in Radical Gastrectomy of Advanced Gastric Cancer

    Objective To evaluate the efficacy and safety of intraoperative mesenchymal chemotherapy with 5-FU implants in radical gastrectomy of advanced gastric cancer. Methods From January 2008 to September 2009, 102 patients with historically proven advanced gastric cancer were enrolled in our department and were allocated to undergo either radical gastrectomy and intraoperative mesenchymal chemotherapy with 5-FU implants 800 mg(treatment group, n=51), or radical gastrectomy alone (control group, n=51). The postoperative complications and recurrence rate between two groups were compared. Results There were no significant differences on the volume of abdominal cavity drainage, count of white blood cells, albumin level, and gastrointestinal adverse events between the two groups (P>0.05). After a median follow-up of 28 months, the local recurrence rate was lower among patients in treatment group than that in control group (16.3% vs. 39.1%, P<0.05), the survival rate of 3-year was higher in treatment group than that in control group (85.8% vs. 67.3%, P<0.05). Conclusions Compared with the control group, there are no significant adverse reactions on patients with advanced gastric cancer who were implanted fluorouraci1 implants during operation, which can reduce local recurrence rates and improve the survival rates.

    Release date:2016-09-08 10:36 Export PDF Favorites Scan
  • Evaluation of Clinical Effects for Advanced Gastric Cancer Combined Multiple Organs Resection( Report of 43 Cases)

    目的 探讨进展期胃癌联合脏器切除的指征和临床效果。方法 回顾性分析我院1998年6月至2008年6月期间施行联合脏器切除的43例进展期胃癌患者的临床资料,并与同期行姑息性手术的29例进展期胃癌患者相比较。结果 术后1、3及5年生存率联合脏器切除患者分别为65.1% (28/43)、30.2% (13/43)及18.6%(8/43),姑息性手术患者分别为41.4% (12/29)、10.3% (3/29)及0 (0/29),前者明显高于后者(P<0.05)。联合脏器切除组并发症发生率为14.0% (6/43),而姑息性手术组并发症发生率为13.8% (4/29),二者比较差异无统计学意义(P>0.05)。结论 进展期胃癌实施联合脏器切除联合术中腹腔内温热化疗等综合治疗,可提高术后生存率。

    Release date:2016-09-08 10:37 Export PDF Favorites Scan
  • Clinical Experience on Laparoscopic Radical Surgery in Patients with Advanced Distal Gastric Cancer (Report of 26 Cases)

    ObjectiveTo summarized the clinical experience on laparoscopic radical surgery in patients with advanced distal gastric cancer. MethodsThe clinical data of 26 patients with advanced distant gastric cancer undergoing laparoscopic gastrectomy were retrospectively analyzed. ResultsLaparoscopic distal gastrectomy was performed successfully in all patients. The operation time was (283.2±27.6) min (270-450 min) and the blood loss was (178.4±67.4) ml (80-350 ml). The time of gastrointestinal function recovery was (2.8±1.2) d (2-4 d), out of bed activity time was (1.5±0.4) d (1-3 d) and liquid diet feeding was (3.5±1.4) d (3-4 d). The hospital stay was (10.0±2.6) d (7-13 d). The number of harvested lymph nodes was 11 to 34 (17.8±7.3). The distance from proximal surgical margin to tumor was (7.0±2.1) cm (5-12 cm) and the distance from distal surgical margin to tumor was (5.5±1.8) cm (4-8 cm), thus surgical margins were negative in all samples. All patients were followed up for 3-48 months (mean 18.5 months), two patients with poorly differentiated adenocarcinoma died of extensive metastasis in 13 and 18 months, respectively, and other patients survived well. ConclusionsLaparoscopic radical gastrectomy with D2 lymphadenectomy for advanced gastric cancer is safe and feasible. However, the advantage of laparoscopic technique over the conventional open surgery requires further study.

    Release date:2016-09-08 10:42 Export PDF Favorites Scan
  • Research Status on Intraoperative Regional Chemotherapy of Advanced Gastric Cancer

    Objective To explore the feasibility, safety, efficacy and mechanism of intraoperative regional chemotherapy of advanced gastric cancer.Methods The related literatures were reviewed and analyzed. Results Compared with systemic chemotherapy, intraoperative regional chemotherapy of advanced gastric cancer could increase blood drug concentration of cancerous tissue, reduce the systemic toxic side effects, increase survival rate and improve the quality of life. Conclusion Intraoperative regional chemotherapy, as an adjuvant treatment of advanced gastric cancer, has been gradually applied to clinic because of the definite curative effect, which is worth popularizing. However, it needs systemic researches and accumulation of cases.

    Release date:2016-09-08 10:50 Export PDF Favorites Scan
  • Laparoscopic-Assisted Radical Gastrectomy in Distant Gastric Cancer (Report of 18 Cases)

    Objective To investigate the feasibility and safety of laparoscopic-assisted gastrectomy for distant gastric cancer. Methods All 18 patients with distant gastric cancer receiving laparoscopic-assisted gastrectomy were analyzed. Results Laparoscopic-assisted distal gastrectomy was performed successfully in all patients. The mean operation time was (291.33±19.61) min. The mean blood loss was (151.32±71.78) ml. The mean numbers of harvested lymph node were 14.57±3.11. The mean time of gastrointestinal function recovery was (3.46±0.93) d, the mean out of bed activity time was (1.75±0.45) d. All patients were followed up for 1-24 months, mean 11 months. No local recurrence, trocar implant or distant metastasis happened. Conclusion Laparoscopic-assisted gastrectomy is a feasible and safe surgical procedure combined with minimal trauma and fast recovery.

    Release date:2016-09-08 10:56 Export PDF Favorites Scan
  • Clinical Study of S-1 plus Oxaliplatin as the First-line Treatment for Patients with Advanced Gastric Cancer

    Objective To evaluate the efficacy and toxicity of the combination of S-1 and oxaliplatin in the first-line chemotherapy of patients with advanced gastric cancer. Methods From March 2012 to April 2013, 57 patients in the First Affiliated Hospital of Guangxi Medical University were enrolled in this study. Oxaliplatin was administered at 130 mg/m2 on day 1, while S-1 was administered orally (< 1.25 m2: 40 mg twice per day; 1.25-1.50 m2: 50 mg twice per day; > 1.50 m2: 60 mg twice per day) for 14 days. The response was evaluated every two chemotherapy cycles. Results The objective response rate was 52.6%, and the disease control rate was 84.2%. The median time to progression was 5.8 months, and the median survival time was 13.5 months. The major grade 3/4 hematological toxic effects were neutropenia (12.3%) and thrombocytope nia (12.3%), and the grade 3/4 non-hematological toxic effects were vomiting, fatigue and sensory neuropathy. The rate of clinical benefit response was 71.9% (41/57). Conclusion The regimen of oxaliplatin and S-1 shows precise efficacy and good tolerance against advanced gastric cancer, and it is worthy of promotion and application in the future.

    Release date: Export PDF Favorites Scan
4 pages Previous 1 2 3 4 Next

Format

Content